A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia.

In the poultry industry, infections with avian influenza virus (AIV) can result in significant economic losses. The risk and the size of an outbreak might be restricted by vaccination of poultry. A vaccine that would be used for rapid intervention during an outbreak should be safe to use, highly effective after a single administration and be suitable for mass application. A vaccine that could be applied by spray or aerosol would be suitable for mass application, but respiratory applied inactivated influenza is poorly immunogenic and needs to be adjuvanted. We chose aluminum OH, chitosan, cholera toxin B subunit (CT-B), and Stimune as adjuvant for an aerosolized vaccine with inactivated H9N2. Each adjuvant was tested in two doses. None of the adjuvanted vaccines induced AIV-specific antibodies after single vaccination, measured 1 and 3 weeks after vaccination by aerosol, in contrast to the intramuscularly applied vaccine. The aerosolized vaccine did enter the chickens' respiratory tract as CT-B-specific serum antibodies were detected after 1 week in chickens vaccinated with the CT-B-adjuvanted vaccine. Chickens showed no adverse effects after the aerosol vaccination based on weight gain and clinical signs. The failure to detect AIV-specific antibodies might be due to the concentration of the inactivated virus.

[1]  R. Wideman,et al.  Influence of feed deprivation on ventilation and gas exchange in broilers: relationship to pulmonary hypertension syndrome. , 1998, Poultry science.

[2]  W. Jiskoot,et al.  Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. , 2008, Vaccine.

[3]  F. Fang,et al.  Comparison of adjuvant efficacy of chitosan and aluminum hydroxide for intraperitoneally administered inactivated influenza H5N1 vaccine. , 2010, DNA and cell biology.

[4]  W. Hinrichs,et al.  Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant , 2010, The AAPS Journal.

[5]  M. G. Koerkamp,et al.  Reduced immune reaction prevents immunopathology after challenge with avian influenza virus: a transcriptomics analysis of adjuvanted vaccines. , 2010, Vaccine.

[6]  M. G. Groot Koerkamp,et al.  Differential gene-expression and host-response profiles against avian influenza virus within the chicken lung due to anatomy and airflow. , 2009, The Journal of general virology.

[7]  D. Umetsu,et al.  Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen , 2001, Nature Immunology.

[8]  A. Takada,et al.  Protective immune response of chickens against Newcastle disease, induced by the intranasal vaccination with inactivated virus. , 1996, Veterinary microbiology.

[9]  I. Capua,et al.  Control of Avian Influenza in Poultry , 2006, Emerging infectious diseases.

[10]  Yi-you Huang,et al.  Effect of lipopolysaccharide on intranasal administration of liposomal Newcastle disease virus vaccine to SPF chickens. , 2009, Veterinary immunology and immunopathology.

[11]  M. Zambon,et al.  Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. , 2009, Vaccine.

[12]  W. Swart,et al.  Efficacy of infectious bronchitis virus vaccinations in the field: association between the α-IBV IgM response, protection and vaccine application parameters , 2010, Avian pathology : journal of the W.V.P.A.

[13]  T. Ichinohe,et al.  Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection , 2005, Journal of Virology.

[14]  Hanzhong Wang,et al.  Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant , 2010, Archives of Virology.

[15]  C. Vervaet,et al.  Deposition of differently sized airborne microspheres in the respiratory tract of chickens , 2006, Avian pathology : journal of the W.V.P.A.

[16]  A. Nomoto,et al.  Total viral genome copies and virus-Ig complexes after infection with influenza virus in the nasal secretions of immunized mice. , 2004, The Journal of general virology.

[17]  H. Tsujimoto,et al.  Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). , 2000, Vaccine.

[18]  J. Remon,et al.  Vaccination of broiler chickens with dispersed dry powder vaccines as an alternative for liquid spray and aerosol vaccination. , 2008, Vaccine.

[19]  P. Rottier,et al.  A Single Immunization with Soluble Recombinant Trimeric Hemagglutinin Protects Chickens against Highly Pathogenic Avian Influenza Virus H5N1 , 2010, PloS one.

[20]  David E. Swayne,et al.  Diseases of poultry. , 2003 .

[21]  T. Ichinohe,et al.  Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant , 2006, Journal of medical virology.

[22]  B. Lambrecht,et al.  The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. , 2010, Veterinary immunology and immunopathology.

[23]  X. Zhang,et al.  A novel influenza A (H1N1) vaccine in various age groups. , 2009, The New England journal of medicine.

[24]  W. Stok,et al.  Conversion of orally induced suppression of the mucosal immune response to ovalbumin into stimulation by conjugating ovalbumin to cholera toxin or its B subunit. , 1994, Vaccine.

[25]  H. HOWES,et al.  Diseases of Poultry , 1941, Nature.

[26]  D. Tang,et al.  Avian Influenza Vaccination in Chickens and Pigs with Replication-Competent Adenovirus–Free Human Recombinant Adenovirus 5 , 2010, Avian diseases.

[27]  R. Read,et al.  Effective nasal influenza vaccine delivery using chitosan. , 2005, Vaccine.

[28]  M. Roberts,et al.  Carbohydrate Biopolymers Enhance Antibody Responses to Mucosally Delivered Vaccine Antigens , 2000, Infection and Immunity.

[29]  Diana van Zoelen,et al.  Dose response effects of avian influenza (H7N7) vaccination of chickens: serology, clinical protection and reduction of virus excretion. , 2009, Vaccine.

[30]  L. Vervelde,et al.  Induction of a local and systemic immune response using cholera toxin as vehicle to deliver antigen in the lamina propria of the chicken intestine. , 1998, Veterinary immunology and immunopathology.

[31]  M. Sangster,et al.  Quantitative analysis of influenza virus-specific B cell memory generated by different routes of inactivated virus vaccination. , 2010, Vaccine.

[32]  J. Rebel,et al.  Highly pathogenic or low pathogenic avian influenza virus subtype H7N1 infection in chicken lungs: small differences in general acute responses , 2011, Veterinary research.

[33]  H. Hammad,et al.  Mechanism of action of clinically approved adjuvants. , 2009, Current opinion in immunology.

[34]  R. Couch,et al.  A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. , 2007, Vaccine.

[35]  F. Fang,et al.  Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. , 2010, Vaccine.

[36]  Sudarisman,et al.  Sialivac: an intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry. , 2009, Vaccine.